Natural Product (NP) Details
General Information of the NP (ID: NP0016) | |||||
---|---|---|---|---|---|
Name |
Silibinin
|
||||
Synonyms |
Silybin; 22888-70-6; Flavobin; Silymarin I; Silybin A; Silybine; Silibinine; Silliver; Silibinin A; Silibininum; Silibinina; Flavobin Spofa; Silymarine I; Silibinin [INN]; Silymarine; Silibininum [INN-Latin]; Silibinine [INN-French]; Silibinina [INN-Spanish]; 7C3MT; UNII-33X338MNE4; EINECS 245-302-5; NSC 651520; Silimarin; Silibin; CHEBI:9144; 33X338MNE4; Silibinin (INN); NSC651520; C25H22O10; NCGC00091057-01; DSSTox_CID_6018; DSSTox_RID_77985; DSSTox_GSID_26018; (2R,3R)-3,5,7-trihydroxy-2-((2R,3R)-3-(4-hydroxy-
Click to Show/Hide
|
||||
Species Origin | Carduus marianus ... | Click to Show/Hide | |||
Carduus marianus | |||||
Disease | Hepatic encephalopathy [ICD-11: DB99] | Phase 2/3 | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C25H22O10
|
||||
PubChem CID | |||||
Canonical SMILES |
COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O
|
||||
InChI |
1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1
|
||||
InChIKey |
SEBFKMXJBCUCAI-HKTJVKLFSA-N
|
||||
CAS Number |
CAS 22888-70-6
|
||||
ChEBI ID | |||||
Herb ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Regorafenib | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | EIF4EBP1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SW48 | CVCL_1724 | Colon adenocarcinoma | Homo sapiens | ||
GEO | CVCL_0271 | Colon carcinoma | Homo sapiens | |||
LIM1215 | CVCL_2574 | Colon adenocarcinoma | Homo sapiens | |||
HCT 15 | CVCL_0292 | Colon adenocarcinoma | Homo sapiens | |||
HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | |||
SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
The combined treatment with regorafenib and silybin induced synergistic anti-proliferative and apoptotic effects by blocking PI3K/AKT/mTOR intracellular pathway. | |||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BIRC3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PSG1 | Molecule Info | |||
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | ROS generation | ||||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca 2+-CaMKII-Sp1 pathway. | |||||
Vorinostat | Mycosis fungoides | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | POLD1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
In-vitro Model | NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | ||
NCI-H358 | CVCL_1559 | Lung adenocarcinoma | Homo sapiens | |||
NCI-H322 | CVCL_1556 | Lung adenocarcinoma | Homo sapiens | |||
In-vivo Model | Six week old athymic (nu/nu) male nude mice were subcutaneously injected with three million exponentially growing H1299 cells mixed with equal volume (1:1) of matrigel on the right flank of each mouse. | |||||
Experimental
Result(s) |
Combinations of SAHA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a). | |||||
Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | KLF4 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | NANOG | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SMMC-7721 | CVCL_0534 | Hepatocellular carcinoma | Homo sapiens | ||
BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | |||
BEL-7404 | CVCL_6568 | Human hepatocellular carcinoma | Homo sapiens | |||
Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
MHCC97-H | CVCL_4972 | Adult hepatocellular carcinoma | Homo sapiens | |||
MHCC97-L | CVCL_4973 | Adult hepatocellular carcinoma | Homo sapiens | |||
HCCLM3 | CVCL_6832 | Adult hepatocellular carcinoma | Homo sapiens | |||
Hepa 1-6 | CVCL_0327 | Hepatocellular carcinoma of the mouse | Mus musculus | |||
H22 | CVCL_H613 | Hepatocellular carcinoma of the mouse | Mus musculus | |||
In-vivo Model | Athymic nude mice or male C57BL/6 mice (aged 4-6 weeks and weighing 16-18g) were injected with Bel-7404 cells or Hepa 1-6 cells subcutaneously in the right foreleg (4*106 cells/mouse). | |||||
Experimental
Result(s) |
Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. | |||||
Trichostatin A | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | POLD1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
In-vitro Model | NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | ||
NCI-H358 | CVCL_1559 | Lung adenocarcinoma | Homo sapiens | |||
NCI-H322 | CVCL_1556 | Lung adenocarcinoma | Homo sapiens | |||
In-vivo Model | Six week old athymic (nu/nu) male nude mice were subcutaneously injected with about three million exponentially growing H1299 cells mixed with equal volume (1:1) of matrigel on the right flank of each mouse. | |||||
Experimental
Result(s) |
Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a). | |||||
IPI-549 | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Biological
Regulation |
Down-regulation | Regulatory T cells and myeloid suppressor cells | ||||
In-vivo Model | 4T1 cells was inoculated subcutaneously into the right mammary glands of female balb/c mice. | |||||
Experimental
Result(s) |
Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment. | |||||
Methotrexate | Leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | Human rhabdomyosarcoma | Rhabdomyosarcoma | Homo sapiens | |||
Experimental
Result(s) |
Silibinin improves the cytotoxicity of methotrexate in chemo resistant human rhabdomyosarcoma cell lines. | |||||
Dicyclohexylcarbodiimide | Prostate cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [8] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | Enterococcus faecium | Microorganism model | Enterococcus faecium | |||
Escherichia coli | Microorganism model | Escherichia coli | ||||
Pseudomonas aeruginosa | Microorganism model | Pseudomonas aeruginosa | ||||
Experimental
Result(s) |
Silybin showed a remarkable synergistic activity in combination with some antibiotic agents against drug-resistant bacteria. | |||||
Mitoxantrone | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [9] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
The combination of silibinin and mitoxantrone exhibits a pattern of synergy in reducing cell viability with increased apoptosis. | |||||
β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
Indole-3-carbinol | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [10] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CDK2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CDK4 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | NFKBIA | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | RB1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Bronchial 1799 and 1198 cells | Healthy | Homo sapiens | |||
Experimental
Result(s) |
Combinations of indole-3-carbinol and silibinin suppress inflammation-driven mouse lung tumorigenesis by modulating critical cell cycle regulators. | |||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [11] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | L-02 | CVCL_6926 | Ovarian cancer | Homo sapiens | ||
A2780 | CVCL_0134 | Ovarian endometrioid adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
silibinin could restore the sensitivity of cisplatin in drug-resistant human ovarian cancer cells and reduce durg-induced hepatotoxicity in cell level. | |||||
γ. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
1,25-dihydroxyvitamin D3 | Congenital alopecia | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [12] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | SNAI2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | VDR | Molecule Info |
Pathway MAP
|
||
In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
SW480R | CVCL_AT68 | Colon adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Silibinin restored 1,25D responsiveness in vitamin D-resistant colon cancer cells by downregulation of Snail1 and Snail2 and upregulation of vitamin D receptor. | |||||
Erlotinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [13] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | |||
LK2 | CVCL_W132 | Ovarian carcinoma | Homo sapiens | |||
PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | |||
293T GNE | CVCL_0V13 | Healthy | Homo sapiens | |||
In-vivo Model | Tumors were grown by implanting 5*106 cells in Matrigel into female SCID mice flanks. | |||||
Experimental
Result(s) |
Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. | |||||
Gefitinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [13] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | |||
LK2 | CVCL_W132 | Ovarian carcinoma | Homo sapiens | |||
PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | |||
293T GNE | CVCL_0V13 | Healthy | Homo sapiens | |||
In-vivo Model | Animal models were constructed by implanting 5*106 PC-9 cells in Matrigel into the flanks of female severe combined immunodeficiency (SCID) mice. | |||||
Experimental
Result(s) |
Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. | |||||
Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [14] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | SLC2A1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression. |